Humacyte is trading 10.62% up at $0.61 after investors reassessed its August 12 earnings update and positive Phase 3 dialysis results.
- V012 showed ATEV outperforming AV fistula; management targeted a supplemental BLA filing during the second half of 2026.
- Second-quarter revenue was $0.4 million, with a potential late-Q2 2027 dialysis launch.
- Reported volume reached 14.86 million shares versus a 6.46 million average.